XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 56.13

Change

-0.08 (-0.14)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.36 (-1.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.02 (-0.04%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.54 (+0.26%)

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.09 (-0.16%)

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.11 (-0.70%)

USD 54.47B
VUSA:F Vanguard Funds Public Limited ..

+0.70 (+0.65%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.53 (+0.49%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-1.50 (-0.63%)

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

-0.01 (-0.11%)

USD 40.89B
0ZC:F Zscaler Inc

+8.46 (+4.34%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.91% 63% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.91% 63% D 64% D
Trailing 12 Months  
Capital Gain 17.70% 64% D 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.70% 64% D 62% D
Trailing 5 Years  
Capital Gain 62.72% 81% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.72% 81% B- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 10.77% 74% C 69% C-
Dividend Return 10.77% 72% C 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.73% 63% D 88% B+
Risk Adjusted Return 100.34% 95% A 96% N/A
Market Capitalization 0.85B 74% C 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike